The Quality Standard, Primary Stability And Clinical Application Of The Fufangqiancao Perfusate

To further research antibacterial components of Rubia cordifolia L. on diary mastitis in clinical application, the bacteriostasis in vitro of ethanol extracts of Rubia cordifolia L. extracted from different solvent and time were studied to screen out effective antibacterial fraction. Fufangqiancao Perfusate for dairy mastitis treatment which were composed of the effective antibacterial prescriptions from Salvia miltiorrhiza Bunge,Rubia cordifolia L. and Sophoraflavescents Ait. had been researched, its quality standard and preliminary stability had been evaluated, and then it was used in clinical for dairy mastitis.1 Antibacterial activity for the components extracted from Rubia cordifolia L..6 pathogens were selected such as Staphylococcus aureus, Streptococcus dysgalactiae, Bacterium acidi lactic, Bacillus coli, Bacillus proteus, Bacillus aeruginosus to screen out the effective components of bacteriostasis in vitro, it shown that the petroleum ether soluble fraction, chloroform ether soluble fraction and ethyl acetate soluble fraction from the extracts of Rubia cordifolia L. which were tested respectively had bacteriostasis effect, and the ethyl acetate soluble fractions of the plant had strong inhibiting effect on 5 pathogens caused dairy mastitis, the petroleum ether soluble fraction and chloroform ether soluble fraction of the plant had the same antibacterial activity on 6 pathogens, while n-butyl alcohol soluble fractions of the plant had little sensitivity, acetone had no inhibiting effect.2 Quality standard for the herbs (medicinal material) and raw medicine. Each herbs were identified by thin layer chromatography (TLC),and the content of salviol IIA from salvia miltiorrhiza were inspected by High-Performance Liquid Chromatography(HPLC) based on China pharmacopoeia (2005). Furthermore, the identified methods for raw medicine of salvia miltiorrhiza, Rubia cordifolia L. and Sophoraflavescents Ait. were established. According to the test result and the requirement of the prescription that the total content of the tanshinone-â…¡A in material should be no less than 0.39%. 3 Quality control standard for the patent medicine. It mainly on the identification of the essential components for preparation, as well as the content determination of the cryptotanshinone and tanshinone-â…¡A for the prescription. The method of identification was so straight, simple and specialized that the accuracy and repeatability were better for the content determination. The prescription could be made that the total content of cryptotanshinone should be more than 0.1869 mg/mL, and that of tanshinone-â…¡A should be more than 0.1490 mg/mL. and that of the total tanshinone should be more than 0.34 mg/mL.4 Primary stability for the preparation. Accelerated test was done on the basis of high-temperature test and illumination test (in strong light), the result showed the preparation was sensitive when exposed to the strong light and high temperature, so it should be preserved at room temperature as to prolong its shelflife.5 Clinical Application for the Fufangshuangshen perfusate. The preparation was used to treat clinical bovine mastitis in 83 cows, among which 42 dairy cows treated with Fufangshuangshen perfusate and 41 dairy cows with penicillin and Streptomycin as control. The overall total of either complete recovery or clinically improved cows with mastitis was 83.3% for Fufangshuangshen perfusate, 76.2% for penicillin and Streptomycin; the average curative rate was 87.8% for Fufangshuangshen perfusate compared to 78.0% for penicillin and Streptomycin.